Trial Profile
Efficacy of tipiracil/trifluridine (TAS-102) in patients with refractory metastatic colorectal cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2017
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary) ; Regorafenib
- Indications Colorectal cancer
- Focus Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- 11 May 2017 New trial record
- 01 May 2017 Results published in the Annals of Oncology